Skip to main content

Research Repository

See what's under the surface

Advanced Search

Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling

Baker, Jillian G.; Hill, Stephen J.; Summers, Roger J.

Authors

Jillian G. Baker

Stephen J. Hill

Roger J. Summers



Abstract

Sir James Black developed β-blockers, one of the most useful groups of drugs in use today. Not only are they being used for their original purpose to treat angina and cardiac arrhythmias, but they are also effective therapeutics for hypertension, cardiac failure, glaucoma, migraine and anxiety. Recent studies suggest that they might also prove useful in diseases as diverse as osteoporosis, cancer and malaria. They have also provided some of the most useful tools for pharmacological research that have underpinned the development of concepts such as receptor subtype selectivity, agonism and inverse agonism, and ligand-directed signalling bias. This article examines how β-blockers have evolved and indicates how they might be used in the future.

Journal Article Type Article
Publication Date Apr 1, 2011
Journal Trends in Pharmacological Sciences
Print ISSN 0165-6147
Electronic ISSN 0165-6147
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 32
Issue 4
APA6 Citation Baker, J. G., Hill, S. J., & Summers, R. J. (2011). Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends in Pharmacological Sciences, 32(4), doi:10.1016/j.tips.2011.02.010
DOI https://doi.org/10.1016/j.tips.2011.02.010
Publisher URL http://www.sciencedirect.com/science/article/pii/S0165614711000320
Copyright Statement Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0

Files

HillEvolution.pdf (252 Kb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0





You might also like



Downloadable Citations

;